Riplex Information

In life sciences M&A, teams rigorously audit scientific risk, clinical data, IP, regulatory pathway. But operational capability? That's assessed through management interviews and site visits. Subjective. Incomplete. The problem: Leadership instability, talent migration, and quality culture issues appear before they hit the P&L. These signals exist, but no one is systematically tracking them. What we do: We find the operational signals that traditional diligence misses: Leadership gaps and turnover at site level Talent migration to competitors Quality team stability Regulatory friction patterns For whom: PE firms, strategic acquirers, and biotech executives making high-stakes decisions about CDMOs, CROs, and manufacturing partners.